Human polymorphonuclear neutrophils (PMN), reactive oxygen species (ROS) and inflammatory reactions are closely interrelated, and increasing attention is being given to the search for new synthetic or natural antioxidant agents, capable of reducing ROS and consequent inflammation. It has been claimed that bisabolol (a monocyclic sesquiterpene alcohol) has an antioxidant/anti-inflammatory activity, but this has almost exclusively been investigated using chemical or biochemical tests. We studied the ability of bisabolol to interfere with ROS production (luminol-amplified chemiluminescence, LACL) during human PMN respiratory bursts induced by both corpusculate(Candida albicans) and soluble stimulants (N-formyl-methionyl-leucyl-phenylalanine, fMLP). LACL was also used to test cell-free systems (SIN-1 and H2O2/HOCl– systems) in order to investigate the presence of scavenging activity. After C. albicans stimulation, significant concentration-dependent LACL inhibition was observed at bisabolol concentrations ranging from 7.7 to 31 μg/ml; after the fMLP stimulus, significant LACL inhibition was observed at bisabolol concentrations ranging from 3.8 to 31 μg/ml. A similar effect was observed in the SIN-1 and H2O2/HOCl– systems. These findings draw the attention to the possible medical use of bisabolol as a means of improving the antioxidant network and restoring the redox balance by antagonising oxidative stress.

Keywords:
Bisabolol, Human neutrophils, Reactive oxygen species production, Chemiluminescence, Antioxidant activity
This content is only available via PDF.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.